Skip to main content

Advertisement

SpringerLink
Log in

IL6-induced metastasis modulators p-STAT3, MMP-2 and MMP-9 are targets of 3,3′-diindolylmethane in ovarian cancer cells

  • Original Paper
  • Published:
Cellular Oncology Aims and scope Submit manuscript

Abstract

Purpose

Ovarian cancer is a highly lethal gynecological malignancy for which the overall prognosis has remained poor over the past few decades. Interleukin (IL6) has been found to be a major contributor to the initiation and progression of ovarian cancer. This cytokine exerts its activity through activation of several signaling pathways, in particular the signal transducer and activator of transcription (STAT3) pathway. Here, we aimed at investigating the capacity of a natural dietary compound found in cruciferous vegetables, i.e., 3,3′-diindolylmethane (DIM), to target the metastatic phenotype of ovarian cancer cells through functional p-STAT3.

Methods

The human ovarian carcinoma-derived cell lines SKOV3 and A2780 were treated with IL6 and/or DIM and subjected to in vitro proliferation, adhesion, migration and invasion assays to assess the anti-metastatic and anti-IL6 effects of DIM, as well as to assess gene expression alterations before and after shRNA-mediated STAT3 silencing.

Results

We found that DIM inhibits IL6-mediated increases in ovarian cancer cell adhesion, migration and invasion. These results were corroborated by shRNA-mediated STAT3 silencing. Through Western blot and ELISA analyses direct evidence was provided for the capacity of DIM to inhibit ovarian cancer cell adhesion, migration and invasion, which was found to be associated with down-regulation of the matrix metalloproteinases MMP-2 and MMP-9.

Conclusions

From our data we conclude that DIM exhibits an anti-IL6-like activity by inhibiting p-STAT3 enhanced ovarian cancer cell proliferation and in vitro metastasis-associated events, i.e., adhesion, migration and invasion. Most significantly, MMP-2 and MMP-9, which are known to promote and enhance metastasis, were found to act as targets of DIM. This anti-IL6-like property of DIM may pave the way for the development of novel ovarian cancer preventive and/or therapeutic strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. S. Vaughan, J.I. Coward, R.C. Bast Jr., A. Berchuck, J.S. Berek, J.D. Brenton, G. Coukos, C.C. Crum, R. Drapkin, D. Etemadmoghadam, M. Friedlander, H. Gabra, S.B. Kaye, C.J. Lord, E. Lengyel, D.A. Levine, I.A. McNeish, U. Menon, G.B. Mills, K.P. Nephew, A.M. Oza, A.K. Sood, E.A. Stronach, H. Walczak, D.D. Bowtell, F.R. Balkwill, Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 11, 719–725 (2011)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Y. Li, K. Wang, Y.Z. Jiang, X.W. Chang, C.F. Dai, J. Zheng, 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD) inhibits human ovarian cancer cell proliferation. Cell Oncol 37, 429–437 (2014)

    Article  CAS  Google Scholar 

  3. M. Momeni, T. Kalir, S. Farag, L. Chuang, D. Fishman, D.E. Burstein, Expression of H1. 5 and PLZF in granulosa cell tumors and normal ovarian tissues: a short report. Cell Oncol 37, 229–234 (2014)

    Article  CAS  Google Scholar 

  4. J. Di, T. Duiveman-de Boer, P.L. Zusterzeel, C.G. Figdor, L.F.G. Massuger, R. Torensma, The stem cell markers Oct4A, Nanog and c-Myc are expressed in ascites cells and tumor tissue of ovarian cancer patients. Cell Oncol 36, 363–374 (2013)

    Article  CAS  Google Scholar 

  5. R. Siegel, J. Ma, Z. Zou, A. Jemal, Cancer statistics, 2014. CA Cancer J Clin 64, 9–29 (2014)

    Article  PubMed  Google Scholar 

  6. R. Agarwal, S.B. Kaye, Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3, 502–516 (2003)

    Article  CAS  PubMed  Google Scholar 

  7. S. McNaughton, A, Marks G C, Development of a food composition database for the estimation of dietary intakes of glucosinolates, the biologically active constituents of cruciferous vegetables. Br J Nutr 90, 687–697 (2003)

    Article  CAS  PubMed  Google Scholar 

  8. K. Kandala, P, K Srivastava S, DIMming ovarian cancer growth. Curr Drug Targets 13(1869–1875) (2012)

  9. P.K. Kandala, S.K. Srivastava, Regulation of Janus-activated kinase-2 (JAK2) by diindolylmethane in ovarian cancer in vitro and in vivo. Drug Discov Ther 6, 94–101 (2012)

    CAS  PubMed  Google Scholar 

  10. L.M. Beaver, T.W. Yu, E.I. Sokolowski, D.E. Williams, R.H. Dashwood, E. Ho, 3, 3′-Diindolylmethane, but not indole-3-carbinol, inhibits histone deacetylase activity in prostate cancer cells. Toxicol Appl Pharmacol 263, 345–351 (2012)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. S. Banerjee, Z. Wang, D. Kong, F.H. Sarkar, 3, 3′-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer. Cancer Res 69, 5592–5600 (2009)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Q.J. Wu, Y. Yang, E. Vogtmann, J. Wang, L.H. Han, H.L. Li, Y.B. Xiang, Cruciferous vegetables intake and the risk of colorectal cancer: a meta-analysis of observational studies. Ann Oncol 24, 1079–1087 (2013)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. B.B. Aggarwal, H. Ichikawa, Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle 4, 1201–1215 (2005)

    Article  CAS  PubMed  Google Scholar 

  14. D. Kong, Y. Li, Z. Wang, S. Banerjee, F.H. Sarkar, Inhibition of angiogenesis and invasion by 3, 3′-Diindolylmethane is mediated by the Nuclear Factor-κB downstream target genes MMP-9 and uPA that regulate bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res 67, 3310–3319 (2007)

    Article  CAS  PubMed  Google Scholar 

  15. A. Aamir, B. Bernhard, L. Yiwei, K. Dejuan, B. Bin, S. Rainer, B. Subhash, H. Fazlul, Sarkar, Targeted regulation of PI3K/Akt/mTOR/NF-κB signaling by indole compounds and their derivatives: mechanistic details and biological implications for cancer therapy. Anticancer Agents Med Chem 13, 1002 (2013)

    Article  Google Scholar 

  16. P.K. Kandala, S.E. Wright, S.K. Srivastava, Blocking epidermal growth factor receptor activation by 3, 3′-diindolylmethane suppresses ovarian tumor growth in vitro and in vivo. J Pharmacol Exp Ther 341, 24–32 (2012)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. A. Maccio, C. Madeddu, Inflammation and ovarian cancer. Cytokine 58, 133–147 (2012)

    Article  CAS  PubMed  Google Scholar 

  18. J. Coward, H. Kulbe, P. Chakravarty, D. Leader, V. Vassileva, D.A. Leinster, R. Thompson, T. Schioppa, J. Nemeth, J. Vermeulen, N. Singh, N. Avril, J. Cummings, E. Rexhepaj, K. Jirström, W.M. Gallagher, D.J. Brennan, I.A. McNeish, F.R. Balkwill, Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 17, 6083–6096 (2011)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Y. Guo, F. Xu, T. Lu, Z. Duan, Z. Zhang, Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 38, 904–910 (2012)

    Article  CAS  PubMed  Google Scholar 

  20. G. Gastl, M. Plante, Bioactive interleukin-6 levels in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Methods Mol Med 39, 121–123 (2001)

    CAS  PubMed  Google Scholar 

  21. E.M. Dijkgraaf, M.J. Welters, J.W. Nortier, S.H. van der Burg, J.R. Kroep, Interleukin-6/interleukin-6 receptor pathway as a new therapy target in epithelial ovarian cancer. Curr Pharm Des 18, 3816–3827 (2012)

    Article  CAS  PubMed  Google Scholar 

  22. Y. Wang, L. Li, X. Guo, X. Jin, W. Sun, X. Zhang, R.C. Xu, Signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells. Cytokine 59, 228–236 (2012)

    Article  CAS  PubMed  Google Scholar 

  23. N. Shah, K. Jin, L.A. Cruz, S. Park, H. Sadik, S. Cho, C.P. Goswami, H. Nakshatri, R. Gupta, H.Y. Chang, Z. Zhang, A. Cimino-Mathews, L. Cope, C. Umbricht, S. Sukumar, HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERα and inducing IL-6 expression. Cancer Res 73, 5449–5458 (2013)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. V.P.S. Garikapaty, B.T. Ashok, K. Tadi, A. Mittelman, R.K. Tiwari, Synthetic dimer of indole-3-carbinol: second generation diet derived anti-cancer agent in hormone sensitive prostate cancer. Prostate 66, 453–462 (2006)

    Article  CAS  PubMed  Google Scholar 

  25. K.M. Rahman, S. Ali, A. Aboukameel, S.H. Sarkar, Z. Wang, P.A. Philip, W.A. Sakr, A. Raz, Inactivation of NF- KB by 3, 3′-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells. Mol Cancer Ther 6, 2757–2765 (2007)

    Article  CAS  PubMed  Google Scholar 

  26. L. Xue, G.L. Firestone, L.F. Bjeldanes, DIM stimulates IFNgamma gene expression in human breast cancer cells via the specific activation of JNK and p38 pathways. Oncogene 24, 2343–2353 (2005)

    Article  CAS  PubMed  Google Scholar 

  27. M. Walter, S. Liang, S. Ghosh, P.J. Hornsby, R. Li, Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells. Oncogene 28, 2745–2755 (2009)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. D. Hanahan, R.A. Weinberg, The hallmarks of cancer. Cell 100, 57–70 (2000)

    Article  CAS  PubMed  Google Scholar 

  29. G.P. Gupta, J. Massagué, Cancer metastasis: building a framework. Cell 127, 679–695 (2006)

    Article  CAS  PubMed  Google Scholar 

  30. B. Tu, L. Du, Q.M. Fan, Z. Tang, T.T. Tang, STAT3 activation by IL-6 from mesenchymal stem cells promotes the proliferation and metastasis of osteosarcoma. Cancer Lett 325, 80–88 (2012)

    Article  CAS  PubMed  Google Scholar 

  31. S. Bellone, K. Watts, S. Cane, M. Palmieri, M.J. Cannon, A. Burnett, xAlexander BurnettSearch for articles by this author Roman JJ, Pecorelli S, Santin AD, High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and Affiliations Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA chemotherapy-resistant variant of endometrial cancer. Gynecol Oncol 98, 92–98 (2005)

    Article  CAS  PubMed  Google Scholar 

  32. N. Songur, B. Kuru, F. Kalkan, C. Ozdilekcan, H. Cakmak, N. Hizel, Serum interleukin-6 levels correlate with malnutrition and survival in patients with advanced non-small cell lung cancer. Tumori 90, 196–200 (2004)

    CAS  PubMed  Google Scholar 

  33. I. Garcia-Tunon, M. Ricote, A. Ruiz, B. Fraile, R. Paniagua, M. Royuela, IL-6, its receptors and its relationship with bcl-2 and bax proteins in infiltrating and in situ human breast carcinoma. Histopathology 47, 82–89 (2005)

    Article  CAS  PubMed  Google Scholar 

  34. R. Salgado, S. Junius, I. Benoy, P. Van Dam, P. Vermeulen, E. Van Marck, P. Huget, L. Dirk, Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 103, 642–646 (2003)

    Article  CAS  PubMed  Google Scholar 

  35. I. Zakrzewska, J. Poznanski, Changes of serum IL-6 and CRP after chemotherapy in patients with ovarian carcinoma. Pol Merkur Lekarski 11, 210–213 (2001)

    CAS  PubMed  Google Scholar 

  36. R.T. Penson, K. Kronish, Z. Duan, A.J. Feller, P. Stark, S.E. Cook, L.R. Duska, A.F. Fuller, A.K. Goodman, N. Nikrui, K.M. MacNeill, U.A. Matulonis, F.I. Preffer, M.V. Seiden, Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1. GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Can 10, 33–41 (2000)

    Article  Google Scholar 

  37. D.G. Rosen, I. Mercado-Uribe, G. Yang, R.C. Bast Jr., H.M. Amin, R. Lai, J. Liu, The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer 107, 2730–2740 (2006)

    Article  CAS  PubMed  Google Scholar 

  38. N. de la Iglesia, S.V. Puram, A. Bonni, STAT3 regulation of glioblastoma pathogenesis. Curr Mol Med 9, 580–590 (2009)

    Article  PubMed Central  PubMed  Google Scholar 

  39. M. Musteanu, L. Blaas, M. Mair, M. Schlederer, M. Bilban, S. Tauber, H. Esterbauer, M. Mueller, E. Casanova, L. Kenner, V. Poli, R. Eferl, Stat3 is a negative regulator of intestinal tumor progression in Apc(Min) mice. Gastroenterology 138, 1003–1011 (2010)

    Article  CAS  PubMed  Google Scholar 

  40. J.P. Couto, L. Daly, A. Almeida, J.A. Knauf, J.A. Fagin, M. Sobrinho-Simoes, J. Lima, V. Maximo, P. Soares, D. Lyden, J. Bromberg, STAT3 negatively regulates thyroid tumorigenesis. Proc Natl Acad Sci U S A 109, 2361–2370 (2012)

    Article  Google Scholar 

  41. J.F. Torres-Roca, M. DeSilvio, L.B. Mora, L.Y. Khor, E. Hammond, N. Ahmad, R. Jove, J. Forman, R.J. Lee, H. Sandler, A. Pollack, Activated STAT3 as a correlate of distant metastasis in prostate cancer: a secondary analysis of Radiation Therapy Oncology Group 86–10. Urology 69, 505–509 (2007)

    Article  PubMed  Google Scholar 

  42. N. Yanaihara, M.S. Anglesio, K. Ochiai, Y. Hirata, M. Saito, C. Nagata, Y. Lida, S. Takakura, K. Yamada, T. Tanaka, A. Okamoto, Cytokine gene expression signature in ovarian clear cell carcinoma. Int J Oncol 41, 1094–1100 (2012)

    CAS  PubMed  Google Scholar 

  43. S. Chakraborti, M. Mandal, S. Das, A. Mandal, T. Chakraborti, Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 253, 269–285 (2003)

    Article  CAS  PubMed  Google Scholar 

  44. S.P. Gao, J.F. Bromberg, Touched and moved by STAT3. Sci. Signaling. 2006, pe30 (2006)

Download references

Acknowledgements

The authors would like to thank the Scientific and Technological Research Program of the Chongqing Municipal Education Commission supported by research funds provided by the Scientific and Technological Research Program of the Chongqing Municipal Education Commission (#CSTC2012gg-yyis10002).

Author information

Authors and Affiliations

  1. Department of Oncology, The Second Affiliated Hospital, Chongqing Medical University, 74 Linjiang Road, Chongqing, 400010, China

    Minghua Zou, Xianquan Zhang & Changhua Xu

Authors
  1. Minghua Zou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xianquan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Changhua Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xianquan Zhang.

Ethics declarations

Competing interests

All authors declare that they have no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zou, M., Zhang, X. & Xu, C. IL6-induced metastasis modulators p-STAT3, MMP-2 and MMP-9 are targets of 3,3′-diindolylmethane in ovarian cancer cells. Cell Oncol. 39, 47–57 (2016). https://doi.org/10.1007/s13402-015-0251-7

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13402-015-0251-7

Keywords

Search

Navigation